Xeljanz XR (Tofacitinib Citrate) Patent Expiration, LOE Window & CMS Spending

Xeljanz XR (Tofacitinib Citrate) by Pfizer: FDA Orange Book core substance LOE 2026-06-08 (last listed 2034-09-14), 10 AB generics, $718.8M 2024 CMS Part D & Medicaid spend, and $5,536 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN208246 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-06-08
Last Listed Patent or Exclusivity Date2034-09-14
Orange Book Patents (*PED Extensions)8 patents (4 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$718.8M
2024 Medicare Part D Spend$589.8M
2024 Medicaid Spend$129.0M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,536 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.